Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA-SEOM group.
A simple blood test (SIRI score) helps predict which pancreatic cancer patients benefit most from different chemotherapy approaches.
SIRI (Systemic Inflammation Response Index, derived from CBC: monocyte × neutrophil / lymphocyte) independently predicts overall survival and differential chemotherapy benefit in metastatic pancreatic cancer, enabling risk-adaptive first-line treatment selection. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Retrospective multicenter cohort (PANTHEIA-SEOM real-world registry)
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- Pancreatology
Why it surfaced
Multicenter real-world validation of a readily available CBC-derived biomarker (SIRI) for prognosis and chemotherapy benefit prediction in pancreatic cancer; directly actionable for treatment selection and connects to the CBC/precision oncology overlap.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.